Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Malignant GliomaGlioblastoma MultiformeGBMAstrocytomaOligodendroglioma
Interventions
DRUG

TM-601

TM-601, administered intravenously (IV), once/week for 3 weeks

Trial Locations (7)

10032

Columbia University, New York

60611

Northwestern University, Chicago

63110

Washington University, St Louis

90048

Cedars-Sinai Medical Center, Los Angeles

35294-3410

University of Alabama, Birmingham

27157-1082

Wake Forest University, Winston-Salem

98195-6470

University of Washington, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

TransMolecular

INDUSTRY

NCT00591058 - Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter